Implantable Exenatide Delivery Device Lowers HbA1c in T2DMImplantable Exenatide Delivery Device Lowers HbA1c in T2DM

The rationale behind the subcutaneous drug-delivery platform is to offer patients an alternative to regular life-long injections and improve patient compliance and convenience, according to study investigators. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news